candesartan cilexetil has been researched along with Dyslipidemia in 2 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated whether pharmacologic treatment of prehypertension prevents or postpones stage 1 hypertension." | 2.72 | Feasibility of treating prehypertension with an angiotensin-receptor blocker. ( Black, HR; Egan, BM; Grimm, RH; Julius, S; Kaciroti, N; Messerli, FH; Michelson, EL; Nesbitt, SD; Oparil, S; Schork, MA; Weber, MA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Julius, S | 1 |
| Nesbitt, SD | 1 |
| Egan, BM | 1 |
| Weber, MA | 1 |
| Michelson, EL | 1 |
| Kaciroti, N | 1 |
| Black, HR | 1 |
| Grimm, RH | 1 |
| Messerli, FH | 1 |
| Oparil, S | 1 |
| Schork, MA | 1 |
| Mann, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Multicenter, Long-term Trial of Preventing Hypertension Using Candesartan Cilexetil 16 mg in Patients With High Normal Blood Pressure (TROPHY)[NCT00227318] | Phase 3 | 1,000 participants | Interventional | 1998-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for candesartan cilexetil and Dyslipidemia
| Article | Year |
|---|---|
Feasibility of treating prehypertension with an angiotensin-receptor blocker.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2006 |
1 other study available for candesartan cilexetil and Dyslipidemia
| Article | Year |
|---|---|
[Treatment of high-normal blood pressure with angiotensin receptor blockers. TROPHY Study (Trial of Preventing Hypertension)].
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2007 |